-
H. J. Kim,
B. K. Jung, J. J. Lee,
K. H. Pyo,
T. Y. Kim,
B. I. Choi,
T. W. Kim,
H. Hisaeda,
K. Himeno,
E. H. Shin,
J. Y. Chai
[show abstract]
[hide abstract]
ABSTRACT: Relatively little has been studied on the AMA-1 vaccine against Plasmodium vivax and on the plasmid DNA vaccine encoding P. vivax AMA-1 (PvAMA-1). In the present study, a plasmid DNA vaccine encoding AMA-1 of the reemerging Korean P. vivax has been constructed and a preliminary study was done on its cellular immunogenicity to recipient BALB/c mice. The PvAMA-1 gene was cloned and expressed in the plasmid vector UBpcAMA-1, and a protein band of approximately 56.8 kDa was obtained from the transfected COS7 cells. BALB/c mice were immunized intramuscularly or using a gene gun 4 times with the vaccine, and the proportions of splenic T-cell subsets were examined by fluorocytometry at week 2 after the last injection. The spleen cells from intramuscularly injected mice revealed no significant changes in the proportions of CD8(+) T-cells and CD4(+) T-cells. However, in mice immunized using a gene gun, significantly higher (P<0.05) proportions of CD8(+) cells were observed compared to UB vector-injected control mice. The results indicated that cellular immunogenicity of the plasmid DNA vaccine encoding AMA-1 of the reemerging Korean P. vivax was weak when it was injected intramuscularly; however, a promising effect was observed using the gene gun injection technique.
The Korean Journal of Parasitology 11/2012; 49(1):85-90. · 1.04 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: To examine the infection status of freshwater fish with Gnathostoma spp. larvae in Myanmar, we purchased 15 snakeheads, Channa striatus, from a local market in a suburban area of Naypyidaw, the new capital city. Two larval gnathostomes were collected using an artificial digestion technique, and observed by a light microscope and a scanning electron microscope. The size of an intact larva was 2.65 mm long and 0.32 mm wide. The characteristic morphology of the larvae included the presence of a long esophagus (0.80 mm long), 2 pairs of cervical sacs (0.43 mm long), and a characteristic head bulb with 4 rows of hooklets. The number of hooklets in the 1st, 2nd, 3rd, and 4th row was 45, 48, 50, and 52, respectively. Based on these morphological characters, the larvae were identified as the advanced 3rd-stage larvae of Gnathostoma spinigerum. This is the first report of detection of G. spinigerum 3rd-stage larvae in the central part of Myanmar. Our study suggests that intake of raw meat of snakehead fish in Myanmar may result in human gnathostomiasis.
The Korean Journal of Parasitology 11/2012; 46:285-8. · 1.04 Impact Factor
-
Lymphoma Study Division of the Korean Cancer Study Group,
Y. H. Park, J. J. Lee,
M. H. Ryu,
S. Y. Kim,
D. H. Kim,
Y. R. Do,
K. H. Lee,
S. J. Oh,
Y. K. Kim, [......],
D. S. Heo,
B. Y. RYoo,
J. K. Kim,
H. S. Song,
W. S. Lee,
H. J. Kim,
Y. J. Bang,
S. H. Yang,
S. K. Sohn,
Y. K. Kang
[show abstract]
[hide abstract]
ABSTRACT: The addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) has been shown to improve the
outcome in all age groups with newly diagnosed diffuse large B-cell lymphoma (DLBCL). We conducted a retrospective analysis
to evaluate the impact of this combination therapy on DLBCL outcomes in Korea. From October 2001 to June 2004, newly diagnosed
DLBCL patients in nine Korean institutes were included. All of these 81 patients were treated with three or more cycles of
rituximab plus CHOP (R-CHOP) combination chemotherapy (R group), and followed for a minimum of 12months. For comparison,
a historical cohort of patients was used and analyzed for “Clinicopathologic characteristics of Korean non-Hodgkin’s lymphomas
(NHLs) based on Revised American Lymphoma (REAL) classification” in 1999. Among the 1,098 NHL patients, the data of 214 DLBCL
patients, who were treated with CHOP chemotherapy in first-line, were analyzed (C group). We compared outcomes between the
C group and the R group. A total of 295 patients were evaluated (C group, 214; R group, 81). The complete response (CR) rate
was higher in R group (73 vs 91%, p=0.001). The 2-year event-free survival (EFS) rate was significantly higher in R group (78 vs 85%, p=0.0194). This survival benefit was maintained in high-risk patients according to the international prognostic index (IPI)
(p=0.0039), regardless of age. However, there was no significant difference in low-risk patients. The addition of rituximab
to CHOP combination chemotherapy for DLBCLs showed improved outcomes, particularly in high-risk group according to the IPI.
Long-term follow-up results will be needed to confirm these results.
Annals of Hematology 04/2012; 85(4):257-262. · 2.62 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Discussions of eosinophils are often descriptions of end-stage effector cells with destructive capabilities mediated predominantly by released cytotoxic cationic granule proteins. Moreover, eosinophils in the medical literature are invariably associated with the pathologies linked with helminth infections or allergic diseases such as asthma. This has led to an almost fatalist view of eosinophil effector functions and associated therapeutic strategies targeting these cells that would make even William of Ockham proud - eosinophil effector functions have physiological consequences that increase patient morbidity/mortality and 'the only good eosinophils are dead eosinophils'. Unfortunately, the strengths of dogmas are also their greatest weaknesses. Namely, while the repetitive proclamation of dogmatic concepts by authoritative sources (i.e. reviews, meeting proceedings, textbooks, etc.) builds consensus within the medical community and lower the entropies surrounding difficult issues, they often ignore not easily explained details and place diminished importance on alternative hypotheses. The goal of this perspective is twofold: (i) we will review recent observations regarding eosinophils and their activities as well as reinterpret earlier data as part of the synthesis of a new paradigm. In this paradigm, we hypothesize that eosinophils accumulate at unique sites in response to cell turnover or in response to local stem cell activity(ies). We further suggest that this accumulation is part of one or more mechanisms regulating tissue homeostasis. Specifically, instead of immune cells exclusively mediating innate host defence, we suggest that accumulating tissue eosinophils are actually regulators of Local Immunity And/or Remodeling/Repair in both health and disease - the LIAR hypothesis; (ii) we want to be inflammatory (pun intended!) and challenge the currently common perspective of eosinophils as destructive end-stage effector cells. Our hope is to create more questions than we answer and provoke everyone to spend countless hours simply to prove us wrong!
Clinical & Experimental Allergy 04/2010; 40(4):563-75. · 5.03 Impact Factor
-
J H Moon,
S N Kim,
B W Kang,
Y S Chae,
J G Kim,
J S Ahn,
Y K Kim,
D H Yang, J J Lee,
H J Kim,
Y J Choi,
H J Shin,
J S Chung,
G J Cho,
S K Sohn
[show abstract]
[hide abstract]
ABSTRACT: Acute GVHD (aGVHD) is an important risk factor for predicting the incidence or severity of chronic GVHD (cGVHD). Transplant outcome can be influenced by the onset time of aGVHD in patients who have received allogeneic PBSC transplants (PBSCTs). The medical records of 134 patients who survived more than 3 months after myeloablative allogeneic PBSCT were retrospectively reviewed. In all, 38 patients (28.4%) developed grade II-IV aGVHD before day +28 (early aGVHD) and 25 patients (18.7%) after day +28 (late aGVHD). The 5-year cumulative incidence of cGVHD was 78.9% in the early-aGVHD group and 56.6% in the late-aGVHD group (P=0.034). The 5-year OS was 51.0% for the early-aGVHD and 80.8% for the late-aGVHD group (P=0.406). Infection was the primary cause of death for the early-aGVHD group (51.4 vs 16.7%, P=0.017), whereas relapse of the primary disease was higher among the patients with late aGVHD, although this was statistically insignificant (58.3 vs 25.7%, P=0.309). In a multivariate analysis, early aGVHD was identified as a risk factor for developing cGVHD (hazard ratio (HR) 2.278, P=0.004). The development of aGVHD early after allogeneic PBSCT increased the risk of cGVHD and infection-related death rate when compared with the late onset of aGVHD.
Bone marrow transplantation 03/2010; 45(10):1540-5. · 3.00 Impact Factor
-
Robotics and Autonomous Systems. 01/2010; 58:239-248.
-
[show abstract]
[hide abstract]
ABSTRACT: The goal of our study was two-fold: (i) develop a robust 3D colony assay methodology to interrogate drug combinations using GelCount and (ii) to develop 2-drug combinations that might be useful in the clinic for the treatment of high-grade gliomas. We used three glioma cell lines (U251MG, SNB19, and LNZ308) and two adenocarcinoma cell lines (MiaPaCa and SW480) grown as colonies in a two-tiered agarose cultures. We evaluated two-drug combinations of difluoromethylornithine (DFMO), carboplatin, vorinostat (SAHA), and docetaxel. To analyze for antitumor efficacy we used GelCount to measure the area under the curve for tumor colony volumes (microm(2) x OD) in each plate. The non-linear dose-response E(max) model and the interaction index based on the Loewe additivity are applied to calculate two-drug synergy, additive, and antagonistic interactions. For glioblastoma cell lines, (i) carboplatin followed by DFMO was synergistic or additive in 2/3 cell lines, (ii) carboplatin before SAHA was synergistic in 1 cell line, (iii) carboplatin before docetaxel was synergistic in 2/3 cell lines and partially additive in the third, (iv) SAHA before docetaxel was synergistic in 1/3 cell lines, (v) docetaxel before DFMO was additive or partially active in 3/3 cell lines, and (vi) DFMO plus SAHA was inactive regardless of order. In the MiaPaCA cell line, synergy occurred when DFMO followed carboplatin and, at short exposure times, when SAHA was combined with carboplatin (regardless of order). In the SW480 cell line synergy occurred only in short exposures for carboplatin followed by docetaxel; additive and mixed partial effects were also seen with DFMO plus carboplatin or docetaxel (regardless of order), carboplatin before DFMO, carboplatin before SAHA, and docetaxel before carboplatin. In conclusion, by applying the Gelcount automated counting and sizing of colonies and the use of E(max) and Loewe models to define drug interactions, we can reliably define drug combination efficacy as a function of log dose and duration of drug exposure.
Technology in cancer research & treatment 05/2009; 8(2):163-76. · 2.02 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: How best to manage advanced esophageal cancer remains unresolved, especially in palliative care. Here, in a pilot study, we evaluated the efficacy and safety of concurrent chemoradiotherapy with S-1 and cisplatin in advanced esophageal cancer. Patients with locally advanced or metastatic squamous cell carcinoma of the esophagus received S-1 and cisplatin at doses of 70 mg/m(2)/day for 14 days and 70 mg/m(2) on day 1, respectively, every 3 weeks. Concurrently, radiotherapy was started at a dose of 200 cGy/day, up to a total of 5400 cGy. After concurrent chemoradiotherapy, additive chemotherapy was repeated up to six cycles. Thirty patients were enrolled in this study; of the 27 in whom efficacy could be evaluated, an objective response rate was seen in 20 (74.1%), including five (18.5%) complete pathologic responses in primary lesions. Improvement of dysphagia was seen in 21 (76%) patients. In patients with stage II or III esophageal cancer, the median progression-free survival and overall survival were 10.6 +/- 0.6 months (95% CI: 9.4-11.8) and 23.0 +/- 5.1 months (95% CI: 13.0-32.9), respectively. In patients with stage IV esophageal cancer, the median progression-free survival and overall survival were 5.4 +/- 1.6 months (95% CI: 2.2-8.6) and 11.6 +/- 1.6 months (95% CI: 8.4-14.8), respectively. The main hematological toxicity was neutropenia, but no neutropenic fever was observed. The major non-hematological toxicities were asthenia and vomiting, mostly of grades 1 and 2. Thus, concurrent chemoradiotherapy with S-1 and cisplatin may be a promising nonsurgical treatment in advanced esophageal cancer.
Diseases of the Esophagus 01/2008; 21(8):697-703. · 1.81 Impact Factor
-
J G Kim,
S K Sohn,
Y S Chae,
D H Yang, J-J Lee,
H-J Kim,
H J Shin,
J S Jung,
W S Kim,
D H Kim,
C Suh,
S J Kim,
H-S Eom,
S H Bae
[show abstract]
[hide abstract]
ABSTRACT: The current study aimed to evaluate the efficacy and toxicity of a combination of intravenous busulfan, cyclophosphamide and etoposide (i.v. Bu/Cy/E) as a conditioning regimen prior to autologous hematopoietic stem cell transplantation in patients with non-Hodgkin's lymphoma (NHL). Sixty-four patients with relapsed/refractory (n=36) or high-risk (n=28) lymphoma were enrolled. The high-dose chemotherapy consisted of i.v. Bu (0.8 mg kg(-1) i.v. q 6 h from day -7 to day -5), Cy (50 mg kg(-1) i.v. on day -3 and day -2) and E (400 mg m(-2) i.v. on day -5 and day -4). The median age was 43 (range 18-65) years, and 39 patients were male. Diffuse large B-cell lymphoma (40.6%) was the most common histological subtype. All evaluable patients achieved an engraftment of neutrophils (median, day 12) and platelets (median, day 13). Hepatic veno-occlusive disease was observed in four patients (three mild, one moderate grade), and two patients (3.1%) died from treatment-related complications. At a median follow-up of 16.4 months, 15 patients (23.4%) exhibited a relapse or progression, while 13 patients (20.3%) had died of disease. The estimated 3-year overall and progression-free survival for all patients was 72.1 and 70.1%, respectively. In conclusion, the conditioning regimen of i.v. Bu/Cy/E was well tolerated and seemed to be effective in patients with aggressive NHL.
Bone Marrow Transplantation 12/2007; 40(10):919-24. · 3.75 Impact Factor
-
Y S Chae,
S K Sohn,
J G Kim,
Y Y Cho,
J H Moon,
H J Shin,
J S Chung,
G J Cho,
D H Yang, J-J Lee,
Y-K Kim,
H-J Kim
[show abstract]
[hide abstract]
ABSTRACT: A regimen of busulfan and cyclophosphamide (BuCy2) is regarded as the standard myeloablative regimen for SCT. This study evaluated the hypothesis that fludarabine can replace cyclophosphamide for myeloablative allogeneic SCT. Ninety-five patients underwent allogeneic SCT from HLA-identical donors, following BuCy2 (n=55) or busulfan+fludarabine (BF, n=40). The efficacy of fludarabine compared to cyclophosphamide was retrospectively evaluated. The BF group exhibited a shorter duration until engraftment (P=0.001), lower incidence of acute and chronic GVHD (P<0.001 and P=0.003, respectively), and non-relapse mortality (NRM) (P=0.039). Furthermore, the event-free survival and overall survival were significantly higher for the BF group compared to the BuCy2 group (P=0.004 and 0.002, respectively). After adjusting for age, the risk status of disease, GVHD prophylaxis and donor type, the BF regimen was found to be an independent favorable risk factor for event-free survival (hazard ratio (HR), 0.181; 95% confidence interval, 0.045-0.720; P=0.016) and overall survival (HR, 0.168; 0.035-0.807; P=0.026). The replacement of cyclophosphamide with fludarabine for myeloablative conditioning seems to be more effective in terms of short-term NRM, and GVHD compared to BuCy2 regimen in allogeneic transplantation.
Bone Marrow Transplantation 10/2007; 40(6):541-7. · 3.75 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Magnetic properties of Ge/MnAs digital heterostructure grown by molecular beam epitaxy are reported. A Ge (1 nm)/MnAs (0.15 nm) digital heterostructure exhibited ferromagnetic ordering below 335 K. More importantly, the Ge (1 nm)/MnAs (0.15 nm) heterostructure shows an n-type conductivity and an anomalous Hall effect at room temperature. Concurrently, the magnetic phase stabilities of the Ge (1 nm)/MnAs (0.15 nm) digital heterostructure have been investigated using the highly precise all-electron full-potential linearized augmented plane-wave (FLAPW) method within the generalized gradient approximation (GGA). A total energy calculations reveal that the ferromagnetic coupling between the Mn atoms is energetically favored over the antiferromagnetic (100) and (110) coupling. The Ge (1 nm)/MnAs (0.15 nm) digital heterostructure also showed a possible half-metallic ferromagnetic phase with a 0.25 eV band gap for the minority spin channel, which indicates a promising possible spintronic application
IEEE Transactions on Magnetics 07/2007; · 1.36 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: High-gain, electronically scanned phased array antennas are commonly used for radar and communications applications. These systems often require thousands of radiating elements, thousands of phase shifters, and hence, reduction in cost, size, and weight of the phase shifters are important goals in reducing the cost of the overall system. This letter presents a new ferrite phase shifter design based on microstrip-line technology that provides reduction in cost, size, and weight as compared to typical ferrite (analog) phase shifters. The design is based on the use of three microstrip lines arranged and fed with phase differences so as to produce circular polarization in the ferrite region. The proposed ferrite phase shifter was designed and simulated at 3 GHz to achieve a phase shift of approximately 360deg in less than an effective wavelength. A prototype was designed and fabricated to provide optimal circular polarization in the ferrite region and measured results show 309deg of phase shift in a wavelength, thus fulfilling the requirements. It is also shown that after calibrating measured values to account for the ratio between the applied external Ampere/turn values to the internally applied H-field value used in the high-frequency structure simulator (HFSS), good agreement may be seen between the simulation and experimental results. Based on this successful initial development, suggestions are made for further design improvements including reducing the number of turns in the biasing coil and minimizing the required input power
IEEE Antennas and Wireless Propagation Letters 02/2007; · 1.37 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Studying and understanding the joint effect of combined treatments is important in pharmacology and in the development of combination therapies. The Loewe additivity model is one of the best general reference models for evaluating drug interactions. Based on this model, synergy occurs when the interaction index is less than one, while antagonism occurs when interaction index is greater than one. We expanded the meaning of the interaction index, and propose a procedure to calculate the interaction index and its associated confidence interval under the assumption that the dose-effect curve for a single agent follows Chou and Talalay's median effect equation. In addition, we review four response surface models based on the Loewe additivity model using a single parameter to determine drug interactions. We describe each of these models in the context of Loewe additivity model and discuss their relative advantages and disadvantages. We also provide S-PLUS/R code for each approach to facilitate the implementation of these commonly used methods.
Journal of Biopharmaceutical Statistics 02/2007; 17(3):461-80. · 1.34 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Recently, US federal aviation administration (FAA) have formally approved the use of passive radio frequency identification tags on individual airline parts. Air bus and Boeing proposed amending the ATA's Specification 2000 to include the use of ISO 18000-3 (13.56 MHz) and 18000-6 (UHF). They also announced plans to develop a single RFID specification to be used by both companies to use RFID tags to identify commercial aircraft parts. This decision will drive a wide adoption of RFID technology in aviation industry. In this paper, we present a RFID enabled aircraft maintenance system which could be integrated with inventory control system and aircraft scheduling system to ensure on time performance and safety of passenger and cargo. We believe our study would give a good guideline for further researches on RFID application in the aviation industry and aircraft part manufacturing industry.
Industrial Informatics, 2006 IEEE International Conference on; 09/2006
-
[show abstract]
[hide abstract]
ABSTRACT: High performance airborne foliage penetrating radar requires an antenna design that is low-profile while providing ultra-wideband operation at lower frequencies (100s of MHz) while optimally offering unidirectional radiation. To achieve the desired unidirectional radiation, a ground plane must be implemented that can match the ultra-wideband operation of the antenna being implemented. The needed ground plane must meet these specifications while being low-profile to maintain an overall low-profile antenna design that will efficiently fit in the aircraft. This paper presents a novel ultra-wideband and low-profile hybrid ground plane design that implements ferrite absorbing material with a mushroom structure EBG design. The presented EBG/ferrite hybrid design offers an operational bandwidth exceeding 12:1 starting at 170 MHz
Antennas and Propagation Society International Symposium 2006, IEEE; 08/2006
-
[show abstract]
[hide abstract]
ABSTRACT: The constantly increasing demand for low-cost electrically steered phased antenna arrays have resulted in a significant need for developing low-cost and high performance phase shifters. The ferrite phase shifter presented in this paper not only minimizes cost by using printed-circuit microstrip technology, but it also offers optimal performance in terms of insertion loss, return loss, and phase shift per unit length. By making various design changes to a previously presented design, including implementing ferrite with a magnetic saturation of 600 Gauss, using substrate materials of higher dielectric constant (9.8), designing all microstrip lines to be 50 Omega, and using quarter wave transformers at both the feed and termination ports, the phase shifter performance met and exceeded set specifications. Specifically, the insertion and return losses both at low and high bias regions were sufficiently and acceptably low, and the phase shifter provided over 360deg of total phase shift in about a wavelength. Higher values of insertion losses during the biasing range from 50 to 80 kA/m, which was observed in the simulation results and conformed experimentally, are still under investigation
Antennas and Propagation Society International Symposium 2006, IEEE; 08/2006
-
Y H Park, J J Lee,
M H Ryu,
S Y Kim,
D H Kim,
Y R Do,
K H Lee,
S J Oh,
Y K Kim,
C W Suh,
D S Heo,
B Y Ryoo,
J K Kim,
H S Song,
W S Lee,
H J Kim,
Y J Bang,
S H Yang,
S K Sohn,
Y K Kang
[show abstract]
[hide abstract]
ABSTRACT: The addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) has been shown to improve the outcome in all age groups with newly diagnosed diffuse large B-cell lymphoma (DLBCL). We conducted a retrospective analysis to evaluate the impact of this combination therapy on DLBCL outcomes in Korea. From October 2001 to June 2004, newly diagnosed DLBCL patients in nine Korean institutes were included. All of these 81 patients were treated with three or more cycles of rituximab plus CHOP (R-CHOP) combination chemotherapy (R group), and followed for a minimum of 12 months. For comparison, a historical cohort of patients was used and analyzed for "Clinicopathologic characteristics of Korean non-Hodgkin's lymphomas (NHLs) based on Revised American Lymphoma (REAL) classification" in 1999. Among the 1,098 NHL patients, the data of 214 DLBCL patients, who were treated with CHOP chemotherapy in first-line, were analyzed (C group). We compared outcomes between the C group and the R group. A total of 295 patients were evaluated (C group, 214; R group, 81). The complete response (CR) rate was higher in R group (73 vs 91%, p=0.001). The 2-year event-free survival (EFS) rate was significantly higher in R group (78 vs 85%, p=0.0194). This survival benefit was maintained in high-risk patients according to the international prognostic index (IPI) (p=0.0039), regardless of age. However, there was no significant difference in low-risk patients. The addition of rituximab to CHOP combination chemotherapy for DLBCLs showed improved outcomes, particularly in high-risk group according to the IPI. Long-term follow-up results will be needed to confirm these results.
Annals of Hematology 05/2006; 85(4):257-62. · 2.62 Impact Factor
-
J G Kim,
S K Sohn,
D H Kim,
J H Baek,
K B Lee,
W S Min,
C C Kim,
M H Lee, J-J Lee,
I-J Chung,
H-J Kim,
J W Lee
[show abstract]
[hide abstract]
ABSTRACT: Few studies have addressed the incidence of graft-versus-host disease (GVHD) or survival after ABO-incompatible allogeneic peripheral blood stem cell transplantation (PBSCT). We analyzed the clinical outcome of ABO incompatibility after allogeneic PBSCT. A total of 89 consecutive adult patients with hematological diseases including 49 ABO-identical, 20 major, 15 minor, and five bidirectional ABO-incompatible transplants were enrolled from four medical centers in Korea. No significant difference in engraftment times, graft failure, or transfusion requirements between groups was noted. A clinical diagnosis of severe immune hemolysis or pure red cell aplasia was not made for any patient after transplantation. The incidence of acute or chronic GVHD did not statistically differ between groups. With a median follow-up duration of 13 months (range, 0.5-61 months), the 3-year overall survival estimates for the ABO-identical, major/bidirectional, and minor group were 44.6.0+/-9.0, 43.1+/-11.6, and 43.8+/-13.5%, respectively (P=0.8652), while the 3-year disease-free survival estimates were 33.8+/-7.6, 39.9+/-11.4, and 45.7+/-13.1%, respectively (P=0.8546). We observed that time to neutrophil, platelet, and red blood cell engraftment, transfusion requirements, incidence of acute or chronic GVHD, relapse, and survival were not influenced by ABO incompatibility after allogeneic PBSCT from HLA-matched sibling donors.
Bone Marrow Transplantation 04/2005; 35(5):489-95. · 3.75 Impact Factor
-
G.J. Quarles,
V.K. Castillo,
M. Dubinskii,
L.D. Merkle,
J.R. Goff,
G.L. Wood,
K.L. Schepler,
D. Zelmon,
S. Guha,
L. Gonzalez,
D. Rush, J.J. Lee,
S.M. Hedge,
J.Q. Dumm,
G.L. Messing,
Sang-Ho Lee
[show abstract]
[hide abstract]
ABSTRACT: In this paper, a comparison of ceramic Nd:YAG manufacturing techniques are presented, including an overview of the coprecipitation process and the solid state reaction process. Merits and risks of each from a commercial manufacturing viewpoint are also presented.
Lasers and Electro-Optics Society, 2004. LEOS 2004. The 17th Annual Meeting of the IEEE; 12/2004
-
Bone Marrow Transplantation 12/2004; 34(10):915-6. · 3.75 Impact Factor
